Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer. The company was founded in 2018 and is based in Cerritos, California.
Frequently asked questions
What sector does Liminatus Pharma, Inc. Class A Common Stock (LIMN) operate in?
Liminatus Pharma, Inc. Class A Common Stock belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Liminatus Pharma, Inc. Class A Common Stock (LIMN) current stock price?
As of the latest data, Liminatus Pharma, Inc. Class A Common Stock stock price is $0.14, with a previous close of $0.15. Liminatus Pharma, Inc. Class A Common Stock lost -$0.01 in the last trading session, representing a -6.6% loss.
What is Liminatus Pharma, Inc. Class A Common Stock (LIMN) current market capitalization?
Liminatus Pharma, Inc. Class A Common Stock market cap is approximately 9.40 million.
What is Liminatus Pharma, Inc. Class A Common Stock (LIMN) Earnings Per Share (EPS)?
The trailing EPS is -$0.25.
What is Liminatus Pharma, Inc. Class A Common Stock (LIMN) EBITDA?
Liminatus Pharma, Inc. Class A Common Stock EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -1.10 million.
Does Liminatus Pharma, Inc. Class A Common Stock (LIMN) pay dividends?
No. Liminatus Pharma, Inc. Class A Common Stock does not pay a dividend.
What is Liminatus Pharma, Inc. Class A Common Stock (LIMN) beta (volatility) score?
Liminatus Pharma, Inc. Class A Common Stock has a beta of 0.736, indicating lower volatility than the overall market.
